@article {OKADA1607, author = {TAKURO OKADA and CHIHIRO FUSHIMI and TAKASHI MATSUKI and ISAKU OKAMOTO and HIROKI SATO and TAKAHITO KONDO and KUNIHIKO TOKASHIKI and TAKUMA KISHIDA and TATSUYA ITO and GAI YAMASHITA and YUSUKE AIHARA and KENJI HANYU and YUKIOMI KUSHIHASHI and TATSUO MASUBUCHI and YUICHIRO TADA and KOUKI MIURA and YUKI HARADA and KAHO MOMIYAMA and TAKU YAMASHITA and GO OMURA and HIDEAKI TAKAHASHI and NOBUHIKO ORIDATE and KIYOAKI TSUKAHARA}, title = {Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma}, volume = {42}, number = {3}, pages = {1607--1613}, year = {2022}, doi = {10.21873/anticanres.15635}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: There are no real-world comparative data of nivolumab doses of 3 mg/kg and 240 mg/body for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). We investigated the efficacy and safety of nivolumab in treating recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) at different doses using real-world data. Patients and Methods: R/M SCCHN patients who received nivolumab were divided into the 3 mg/kg and 240 mg/body groups and retrospectively examined for efficacy and safety. Results: A total of 199 patients (3 mg/kg and 240 mg/body, 88 and 111 patients, respectively) were included. The 3 mg/kg vs. 240 mg/body groups had similar overall response rates (15\% vs. 25, p=0.15), disease control rates (46\% vs. 57\%, p=0.15), overall survival (9.5 months vs. 10.9 months), and progression-free survival (3.7 months vs. 3.8 months, p=0.95). The incidence of immune-related adverse events was also similar in both groups. Conclusion: In R/M SCCHN patients, nivolumab showed similar efficacy and safety at doses of 3 mg/kg and 240 mg/body.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/42/3/1607}, eprint = {https://ar.iiarjournals.org/content/42/3/1607.full.pdf}, journal = {Anticancer Research} }